Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial

What Was Tested

Researchers studied Oxytocin and Carbetocin in the context of hyperparathyroidism in this randomized controlled trial publication.

Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by endocrine and neuropsychiatric problems including hyperphagia, anxiousness, and distress.

Intranasal carbetocin, an oxytocin analog, was investigated as a selective oxytocin replacement therapy.

Who Took Part

The abstract describes 130 participants taking part.

The age groups tagged for this paper are children.

A total of 130 participants with PWS aged 7 to 18 years.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Oxytocin.

Some participants received a placebo instead of Oxytocin, giving a reference point.

Randomized, double-blind, placebo-controlled phase 3 trial with long-term follow-up.

Twenty-four ambulatory clinics at academic medical centers.

What Was Measured

Topics PubMed links to this paper include Prader-Willi Syndrome, Oxytocin, Pandemics, COVID-19, Hyperphagia and Anxiety.

Author keywords: carbetocin and vasopressin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin and Carbetocin in 130 participants in people with hyperparathyroidism.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Oxytocin compound page and the Carbetocin compound page, Hyperparathyroidism research.